34193 Psoriasiform eruption after treatment with pembrolizumab

Abstract

Immune checkpoint inhibitors, such as the programmed cell death protein 1 (PD-1) inhibitors, are gaining popularity in the treatment of several types of cancer, and function by stimulating the immune system’s antitumor activity. Immune-related adverse events are common following the use of immune checkpoint inhibitors with rash being the most frequent complaint. Herein, we present the case of a 67-year-old woman with a history of plaque psoriasis and metastatic squamous cell carcinoma of the lung who presented with widespread well-defined erythematous scaly plaques following a dose increase of pembrolizumab (a PD-1 inhibitor).While cutaneous adverse events are common with the use of PD-1 inhibitors, they most frequently manifest as morbilliform eruptions.